Medicare "Least Costly Alternative" Nixed By Courts, But Could Reform Bill's IMAB Convey New Authority?
Executive Summary
A federal appeals court has upheld a lower court's determination that Medicare statutes do not allow the program to limit reimbursement for a drug under Part B to the rate for a "least costly alternative" drug
You may also be interested in...
US Sen. Cassidy On Drug Costs: Exclusivity Based on Innovation, Reference Pricing Proposed
White paper released by Sen. Cassidy, R-La., and upcoming hearing at Senate Health, Education, Labor and Pensions Committee are aimed at building consensus around legislation to lower prices.
Part B Reference Pricing Faces 'Clinical' As Well As 'Political' Obstacles
Medicare pilot program on value-based purchasing could be challenged by a lack of therapeutic consensus as much as by opposition towards reduced reimbursement.
Part B Demo Concerns Unite Policy Experts Across Political Spectrum
Former Democratic congressional staffers agree with Republican health policy experts there is little to like about the proposed Medicare Part B drug payment demonstration.